ELLIPTA DPI

DEVICE4 trials

Sponsors

GlaxoSmithKline

Conditions

Asthma

Phase 3

A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma

CompletedNCT02924688

GlaxoSmithKlineAsthma

Start: 2016-10-13End: 2019-02-22Updated: 2021-03-26

Effectiveness of Fluticasone Furoate/ Umeclidinium/ Vilanterol (FF/UMEC/VI) Using the Connected Inhaler System (CIS) as Compared With Fluticasone Proprionate/ Salmeterol (FP/SAL) Plus Tiotropium (TIO) in Inadequately Controlled Asthma

WithdrawnNCT03376932

GlaxoSmithKlineAsthma

Start: 2019-01-18End: 2021-02-03Updated: 2019-03-25

Phase 4

Phase IV Study in Asthma Subjects for Dry Powder Inhaler (DPI) Versus (vs) Metered Dose Inhaler (MDI) Correct Use

CompletedNCT02794480

GlaxoSmithKlineAsthma

Start: 2016-08-22End: 2016-12-15Updated: 2019-07-02

An Open-label Study to Evaluate Correct Use and Ease of Use of the ELLIPTA DPI in Pediatric Subjects With Asthma

CompletedNCT03478657

GlaxoSmithKlineAsthma

Start: 2018-06-18End: 2018-12-07Updated: 2021-03-26

Related Papers

Is Clinical Remission, an Ambitious Treatment Goal, Achievable in Patients with Moderate-to-Severe Asthma on Inhaled Therapies: How Ambitious Should We Be?

MDPI (MDPI AG)2026-02-14

Evaluating Asthma Clinical Remission with Inhaled Therapy: Post Hoc Analyses of CAPTAIN.

2025-12-24

Baseline Characteristics and ICS/LAMA/LABA Response in Asthma: Analyses From the CAPTAIN Study.

2024-02-014 citations

Clinic vs Home Spirometry for Monitoring Lung Function in Patients With Asthma.

2023-06-2722 citations

CAPTAIN: Improvements in airflow obstruction in patients with uncontrolled asthma

2021-09-05

CAPTAIN: Effects of triple therapy on FEV1 response in patients with inadequately controlled asthma on ICS/LABA

2021-09-05

CAPTAIN: Effects of lung function at screening (FEV1 % predicted) as a continuous variable on treatment outcomes

2021-09-05

CAPTAIN: Relationship between FEV1 reversibility at screening as a continuous variable and treatment response

2021-09-05

Efficacy and safety of once-daily, single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol in Japanese patients with inadequately controlled asthma: the CAPTAIN study.

2021-07-148 citations

Population Pharmacokinetic Modeling of Fluticasone Furoate, Umeclidinium Bromide, and Vilanterol in Patients with Asthma, Using Data from a Phase IIIA Study (CAPTAIN).

2021-02-181 citations

The evaluation of the correct use and ease‐of use of the ELLIPTA DPI in children with asthma

Pediatric Pulmonology2020-10-301 citations

Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial.

2020-09-09173 citations

Characterising asthma exacerbations in the CAPTAIN trial

2020-09-072 citations

CAPTAIN: Effects of age on response to triple therapy in patients with inadequately controlled asthma on ICS/LABA

2020-09-071 citations

CAPTAIN: Effects of smoking status on response to triple therapy in patients with inadequately controlled asthma on ICS/LABA

2020-09-071 citations

A phase IIb, randomised, parallel-group study: the efficacy, safety and tolerability of once-daily umeclidinium in patients with asthma receiving inhaled corticosteroids

Respiratory Research2020-06-1215 citations